Researchers at the University of Illinois Urbana-Champaign report that a brain signaling protein called PSD-95 may be a useful therapeutic target for neurological problems caused by a deletion in MEF2C, a gene linked to autism. The work, led by Nien-Pei Tsai, a professor of molecular and integrative physiology, was done in mice and appears in a new study.
MEF2C is implicated in a range of conditions, including autism, epilepsy and Alzheimer's disease. People with MEF2C haploinsufficiency have only one working copy of the gene instead of the usual two, and the condition is characterized by intellectual disability, autism spectrum disorder and seizures. Tsai noted that while the condition itself is rare, the MEF2C protein is tied to many other disorders, so understanding it may inform research on a broader set of neurodevelopmental conditions.
Tsai's earlier work had linked MEF2C haploinsufficiency to PSD-95, a protein also associated with epilepsy and Alzheimer's. In the new study, the team reasoned that lower MEF2C would cause PSD-95 to accumulate because it was not being broken down properly. Mice carrying only one copy of MEF2C did show elevated PSD-95 in their brains, along with severe seizures and impairments in recognizing novel objects and other mice.
The researchers then reduced PSD-95 in two ways: by breeding mice with only one copy of the PSD-95 gene, and by giving a drug that blocks PSD-95 from interacting with its receptor in neurons. In both cases, the mice's object and social recognition were restored, and their seizures returned to the range seen in normal mice. First author Meijin Pan, a graduate student, said the results suggest PSD-95 could be a target for reducing seizures and rescuing some cognitive function in MEF2C haploinsufficiency or other conditions that lower MEF2C.
The next step is to examine the NMDA receptor, which PSD-95 interacts with and which is a major calcium channel driving neural signaling. The team also wants to map the downstream effects of excess PSD-95 to find other possible targets. Tsai said the aim is to identify new targets or drugs that act specifically on this pathway.